Skip to main content Skip to search

Tumor Microenvironment and Immunotherapy

Publications

2025

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L (2025).

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

LUNG CANCER. Article. 209.
[doi:10.1016/j.lungcan.2025.108763]
Gomez-Randulfe, I, Monaca, F, Cantale, O, Reale, ML, Mrak, L, Zullo, L, Diaz, SS, Bueno, MZ, Moreno, MAM, Davis, C, Cox, S, Lee, D, Shah, R, Geldart, T, Baena, J, Benitez, JC, Campelo, MARG, Remon, J, Planchard, D, Galetta, D, Tiseo, M, Cortinovis, D, Metro, G, Bria, E, Passiglia, F, Novello, S, Califano, R (2025).

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

LUNG CANCER. Article. 209.
[doi:10.1016/j.lungcan.2025.108797]
Li, J, Deng, T, Gu, YH, Blanco, AC, Li, ZH, Bai, CM, Wu, L, Huang, J, Li, XY, Yao, Y, Song, ZB, Li, YS, Liu, L, Xing, LG, Wu, WM, Martinez-Perez, J, Hubert, A, Zugazagoitia, J, Zhang, J, Wang, YS, Zhao, YQ, Wen, GL, Xia, GH, Zhong, DS, Chen, XQ, Jiang, KR, Wang-Gillam, A, Ding, YL, Liu, SM, Rao, ZY, Liu, XH, Shen, L (2025).

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications. Article. 45(11):1500-1512.
[doi:10.1002/cac2.70056]
Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V (2025).

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

LUNG CANCER. Article. 209.
[doi:10.1016/j.lungcan.2025.108799]
Cortellini, A, Santo, V, Brunetti, L, Garbo, E, Pinato, DJ, La Cava, G, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Alessi, JV, Montrone, M, Owen, DH, Ramella, S, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, D'Alessio, A, Banna, GL, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Balachandran, K, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Sforza, V, Tiseo, M, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Rocco, D, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Fitzpatrick, O, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Piedra, A, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Rogado, J, Moliner, L, Nadal, E, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJV, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Peters, S, Wakelee, HA, Nassar, AH, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V (2025).

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 =50%: insights from the pembrolizumab 5-year global registry

Journal For Immunotherapy Of Cancer. Article. 13(9).
[doi:10.1136/jitc-2025-012423]
Falcón, A, Ponce, S, Cote, GM, Gil, A, Lin, JJ, Bockorny, B, Martinez, J, Kahatt, C, Martinez, S, Zubiaur, P, Siguero, M, Cullell-Young, M, Jimenez, J, Zugazagoitia, J, Paz-Ares, L (2025).

Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors

INVESTIGATIONAL NEW DRUGS. Article. 43(4):955-967.
[doi:10.1007/s10637-025-01583-y]
Nassar, AH, Kim, C, Adeyelu, T, Farhat, EB, Abushukair, H, Rakaee, M, Matteson, K, Lau, SF, Takabe, Y, Ocejo, A, Ardeshir-Larijani, F, Leal, T, Ramalingam, S, Alam, S, Gray, JE, Hicks, J, Kaldas, D, Baena, J, Berjaga, MZ, Nana, FA, Grohe, C, Leuders, H, Citarella, F, Cortellini, A, Mingo, EC, Pancirer, D, Das, M, Ellis-Caleo, TJ, Cheung, JM, Lin, JJ, Watson, AS, Camidge, DR, Sridhar, A, Parikh, K, Crowley, F, Marron, TU, Aggarwal, V, Ahmed, M, Sankar, K, Kawtharany, H, Zhang, J, Owen, DH, Li, MJ, Nagasaka, M, Pinato, DJ, Awosika, N, Alhamad, K, Puri, S, Zaman, U, Gupta, DM, Lau, C, Khan, H, Liauw, J, Velazquez, AI, Brown, T, Moliner, L, Mosteiro, M, Rocha, P, Evans, M, Vanderwalde, A, Elliott, A, Nieva, J, Lopes, G, Ma, PC, Borghaei, H, Lee, MT, Young, L, Aljumaily, R, Mirza, H, Kwiatkowski, DJ, Herbst, RS, Flavell, RA, Naqash, AR, Chiang, AC (2025).

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

NATURE COMMUNICATIONS. Article. 16(1).
[doi:10.1038/s41467-025-63091-0]
del Rey-Vergara, R, Galindo-Campos, MA, Rocha, P, Carpes, M, Martínez, C, Masfarré, L, Menéndez, S, Quimis, F, Rossell, A, Iñañez, A, Pérez-Buira, S, Rojo, F, Gimeno, R, Isla, D, Zugazagoitia, J, Blanco, CM, García-Campelo, R, Moreno-Vega, A, León-Mateos, L, Mellén, AC, Park, KS, Heeke, S, Heymach, JV, Taus, A, Paz-Ares, L, Rovira, A, Arriola, E (2025).

MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer

Cell Reports Medicine. Article. 6(7).
[doi:10.1016/j.xcrm.2025.102194]
Cirauqui, C, Ojeda, L, Otano, I, Pazos, I, Santos, A, Garrido-Martín, EM, Yagüe, P, Ramos-Paradas, J, Molina-Pinelo, S, Roncador, G, Solórzano, JL, Muñoz, MT, Cozar, P, Plaza, P, Suárez, R, Jiménez, M, Moreno, R, Rosado, A, Gámez, P, García-Luján, R, Zugazagoitia, J, Sweet-Cordero, EA, Barbacid, M, Carnero, A, Ferrer, I, Paz-Ares, L (2025).

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

Clinical and Translational Medicine. Article. 15(7).
[doi:10.1002/ctm2.70374]
Spira, AI, Paz-Ares, L, Han, JY, Shih, JY, Mascaux, C, Roy, UB, Zugazagoitia, J, Kim, YJ, Chiu, CH, Kim, SW, Nadal, E, Gil-Bazo, I, Murphy, SP, Anderson, BG, Xia, YC, Wang, GR, Bauml, JM, Chioda, M, Simoes, J, Mahadevia, PJ, Lopes, G (2025).

Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report

JOURNAL OF THORACIC ONCOLOGY. Article. 20(6):809-816.
[doi:10.1016/j.jtho.2025.01.018]
Nadal, E, Morán, T, Estival, A, Sala, MA, Antoñanzas, M, González, JG, Diz-Taín, MP, Martínez, M, Azcona, E, Baena, J, Campos, B, Cumplido, JD, Cerezo, S, Díaz-Serrano, A, Guirado, M, Mielgo, X, Saigí, M, Vidales, Z (2025).

Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer

Esmo Real World Data And Digital Oncology. Article. 8.
[doi:10.1016/j.esmorw.2025.100125]
Paz-Ares, L, Gupta, B, Baena, J, Liu, S (2025).

Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer

Clinical Lung Cancer. Article. 26(3):168-178.
[doi:10.1016/j.cllc.2025.02.015]
Varela, M, Teixidó, C, Alvarez-Fernández, C, Arasanz, H, Peralta, S, Lázaro, M, Calvo, V, Alvarez, R, Baena, J, Valdivia, J, Arriola, E, Bernabé, R, Isla, D, Camacho, C, Massutí, B, Blasco, A, García, T, Cobo, M, Campayo, M, Hijazo-Pechero, S, Callejo, A, Dominguez, M, Nadal, E (2025).

Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

Translational lung cancer research. Article. 14(4).
[doi:10.21037/tlcr-2024-1146]
Sereno, M, Collazo-Lorduy, A, Garitaonaindia, Y, de Antonio, DG, Espinar, JB, de la Rosa, CA, Castellanos, PC, Martínez, SF, Valverde, LEC, López-Castro, R, López-Martin, A, Rubio-Pérez, J, Rueda, AG, Puchol, CT, Rubio, XM, Vila, BL, Rogado, J, Hertfelder, EB, Sainz, LG, Campo-Cañaveral, J, Romano,, Thuissard, I, Romero, GR, Sáenz, EC (2025).

Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1

Cancer Treatment and Research Communications. Review. 43.
[doi:10.1016/j.ctarc.2025.100910]
Nassar, AH, Abou Alaiwi, S, El Zarif, T, Denu, R, Macaron, W, Abdel-Wahab, N, Freeman, D, Vasbinder, A, Hayeck, S, Anderson, E, Goodman, RS, Johnson, DB, Grynberg, S, Shapira, R, Kwan, JM, Woodford, R, Long, G, Haykal, T, Dent, S, Kojima, Y, Yonemor, K, Tandon, A, Trevino, A, Akhter, N, Yang, EH, Hui, GV, Drakaki, A, El-Am, E, Kozaily, E, Al-Hader, A, Farhat, EB, Babu, P, Mittra, A, Li, MJ, Jones, N, Baena, J, Herrera, MJ, Foderaro, S, Nana, FA, Kim, C, Sackstein, P, Parikh, K, Desai, AP, Smith, C, Cortellini, A, Pinato, DJ, Korolewicz, J, Lopetegui-Lia, N, Funchain, P, Choudhary, A, Asnani, A, Navani, V, Meyers, D, Stukalin, I, Gallegos, JA, Trent, J, Nusrat, S, Malvar, C, Mckay, RR, Neilan, TG, Choueiri, TK, Naqash, AR (2025).

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study

Journal For Immunotherapy Of Cancer. Article. 13(3).
[doi:10.1136/jitc-2024-009364]
Bote-de Cabo H, Siringo M, Conde E, Hernández S, López-Ríos F, Castelo-Loureiro A, García-Lorenzo E, Baena J, Herrera M, Enguita AB, Ruano Y, Zugazagoitia J, Paz-Ares L (2025).

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC.

Jto Clinical And Research Reports. Article. 6(3):100778-100778.
[doi:10.1016/j.jtocrr.2024.100778]
Calles, A, Alonso, M, Martín-Martorell, P, Gómez, A, de Castro, J, Martínez-Aguillo, M, Estival, A, Mosquera, J, Martínez-Banaclocha, N, Majem, M, Reyes, R, Azkona, E, Ortega, AL, Aguin, S, Santos, A, Aguilar, A, Cucurull, M, Blasco, A, Calvo, V, Isla, D, Nadal, E, Aguado, C, Sais, E, Juan-Vidal, O, Diz-Taín, M, Taus, A, Villanueva, N, Bayona, C, Amenedo, M, Mielgo, X, Arriola, E, Baena, J (2025).

Efficacy and safety of lorlatinib in patients with ALK-and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Cancer Treatment and Research Communications. Article. 43.
[doi:10.1016/j.ctarc.2025.100905]
Ramos-Guerra, AD, Farina, B, Pérez, JR, Vilalta-Lacarra, A, Zugazagoitia, J, Peces-Barba, G, Seijo, LM, Paz-Ares, L, Gil-Bazo, I, Gómez, MD, Ledesma-Carbayo, MJ (2025).

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

CANCER IMMUNOLOGY IMMUNOTHERAPY. Article. 74(4).
[doi:10.1007/s00262-025-03966-9]
Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B (2025).

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Journal For Immunotherapy Of Cancer. Article. 13(2).
[doi:10.1136/jitc-2024-010674]

2024

Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

OncoImmunology. Article. 13(1):2392897-2392897.
[doi:10.1080/2162402X.2024.2392897]
Santoro, A, Pilar, G, Tan, DSW, Zugazagoitia, J, Shepherd, FA, Bearz, A, Barlesi, F, Kim, TM, Overbeck, TR, Felip, E, Cai, C, Simantini, E, Mcculloch, T, Schaefer, ES (2024).

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

BMC CANCER. Article. 24(1):1307-1307.
[doi:10.1186/s12885-024-12841-2]
Molero, A, Hernandez, S, Alonso, M, Peressini, M, Curto, D, Lopez-Rios, F, Conde, E (2024).

Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms

JOURNAL OF CLINICAL PATHOLOGY. Article. 78:456-464.
[doi:10.1136/jcp-2024-209766]
Zugazagoitia, J, Osma, H, Baena, J, Ucero, AC, Paz-Ares, L (2024).

Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer

CLINICAL CANCER RESEARCH. Review. 30(14):2872-2883.
[doi:10.1158/1078-0432.CCR-23-1159]
Peressini, M, Garcia-Campelo, R, Massuti, B, Marti, C, Cobo, M, Gutiérrez, V, Dómine, M, Fuentes, J, Majem, M, de Castro, J, Córdoba, JF, Diz, MP, Isla, D, Esteban, E, Carcereny, E, Vila, L, Moreno-Vega, A, Ros, S, Moreno, A, García, FJ, Huidobro, G, Aguado, C, Cebey-López, V, Valdivia, J, Palmero, R, Lianes, P, López-Brea, M, Vidal, OJ, Provencio, M, Arriola, E, Baena, J, Herrera, M, Bote, H, Molero, M, Adradas, V, Ponce-Aix, S, Nuñez-Buiza, A, Ucero, A, Hernandez, S, Lopez-Rios, F, Conde, E, Paz-Ares, L, Zugazagoitia, J (2024).

Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

CLINICAL CANCER RESEARCH. Article. 30(14):3036-3049.
[doi:10.1158/1078-0432.CCR-24-0104]
Nassar, AH, Kim, SY, Aredo, J, Feng, JM, Shepherd, F, Xu, C, Kaldas, D, Gray, JE, Dilling, TJ, Neal, JW, Wakelee, HA, Liu, YF, Lin, SH, Abuali, T, Amini, A, Nie, YA, Patil, T, Lobachov, A, Bar, J, Fitzgerald, B, Fujiwara, Y, Marron, TU, Thummalapalli, R, Yu, HLA, Owen, DH, Sharp, J, Farid, S, Rocha, P, Arriola, E, 'Aiello, A, Cheng, HY, Whitaker, R, Parikh, K, Ashara, Y, Chen, LX, Sankar, K, Harris, JP, Nagasaka, M, Ayanambakkam, A, Velazquez, AI, Ragavan, M, Lin, JJ, Piotrowska, ZF, Wilgucki, M, Reuss, J, Luders, H, Grohe, C, Espinar, JB, Feiner, E, Punekar, SR, Gupta, S, Leal, T, Kwiatkowski, DJ, Mak, RH, Adib, E, Naqash, AR, Goldberg, SB (2024).

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

JOURNAL OF THORACIC ONCOLOGY. Article. 19(6):928-940.
[doi:10.1016/j.jtho.2024.01.012]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Apr, 10.1007/s40265-024-02030-7, 2024)

DRUGS. Correction. 84(5):621-621.
[doi:10.1007/s40265-024-02044-1]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

DRUGS. Review. 84(5):527-548.
[doi:10.1007/s40265-024-02030-7]

2023

Siringo M, Baena J, Bote de Cabo H, Torres-Jiménez J, Zurera M, Zugazagoitia J, Paz-Ares L (2023).

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.

Cancers. Review. 15(23).
[doi:10.3390/cancers15235505]
García-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, OJ, Cruz-Castellanos, P, Morán, T, Reguart, N, Zugazagoitia, J, Dómine, M (2023).

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023)

Clinical & Translational Oncology. Correction. 25(9):2760-2762.
[doi:10.1007/s12094-023-03290-7]
Ponce, S, Cedrés, S, Ricordel, C, Isambert, N, Viteri, S, Herrera-Juarez, M, Martinez-Marti, A, Navarro, A, Lederlin, M, Serres, X, Zugazagoitia, J, Vetrhus, S, Jaderberg, M, Hansen, TB, Levitsky, V, Paz-Ares, L (2023).

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Journal For Immunotherapy Of Cancer. Article. 11(9).
[doi:10.1136/jitc-2023-007552]
García-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Morán, T, Reguart, N, Zugazagoitia, J, Dómine, M (2023).

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

Clinical & Translational Oncology. Article. 25(9):2679-2691.
[doi:10.1007/s12094-023-03216-3]
Isla, D, Sánchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabé, R (2023).

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Journal of Clinical Medicine. Article. 12(15).
[doi:10.3390/jcm12155063]
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A (2023).

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

CANCER RESEARCH. Article. 83(15):2513-2526.
[doi:10.1158/0008-5472.CAN-22-3023]
Hernandez, S, Conde, E, Alonso, M, Illarramendi, A, de Cabo, HB, Zugazagoitia, J, Paz-Ares, L, Lopez-Rios, F (2023).

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

Translational lung cancer research. Review. 12(7):1549-1562.
[doi:10.21037/tlcr-22-855]
i+12 english
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can also learn more about our Cookie policy and Data protection policy.